Skye Bioscience Inc. (SKYE)
NASDAQ (NMS) NASDAQ (NMS) Primary 
XMUN 
Skye Bioscience Inc Investors Urged To Join The Fraud Investigation With The Schall Law Firm
LOS ANGELES, CA / ACCESSWIRE / August 13, 2024 / The Schall Law Firm , a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Skye Bioscience, Inc. ("Skye" or "the Company") (NASDAQ: SKYE ) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.
Shareholders that lost money on Skye Bioscience, Inc.(SKYE) should contact Levi & Korsinsky about Securities Fraud Investigation - SKYE
NEW YORK, NY / ACCESSWIRE / August 12, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of Skye Bioscience, Inc. ("Skye") (NASDAQ:SKYE) concerning possible violations of federal securities laws. Skye issued a press release on June 10, 2024, "announc[ing] that its Phase 2a clinical trial of SBI-100 Ophthalmic Emulsion ("OE") in patients with primary open-angle glaucoma "POAG") or ocular hypertension ("OHT") did not meet its primary endpoint for lowering intraocular pressure ("IOP").
Skye Bioscience, Inc. (SKYE) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Investors to Seek Compensation for Alleged Wrongdoings
NEW YORK, NY / ACCESSWIRE / August 12, 2024 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Skye Bioscience, Inc. ("Skye" or "the Company") (NASDAQ:SKYE). Investors who purchased Skye securities are encouraged to obtain additional information and assist the investigation by visiting the firm's site: bgandg.com/SKYE.
Levi & Korsinsky Investigates Possible Securities Fraud Violations by Skye Bioscience, Inc. (SKYE)
NEW YORK, NY / ACCESSWIRE / August 11, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of Skye Bioscience, Inc. ("Skye") (NASDAQ:SKYE) concerning possible violations of federal securities laws. Skye issued a press release on June 10, 2024, "announc[ing] that its Phase 2a clinical trial of SBI-100 Ophthalmic Emulsion ("OE") in patients with primary open-angle glaucoma "POAG") or ocular hypertension ("OHT") did not meet its primary endpoint for lowering intraocular pressure ("IOP").
Skye Bioscience, Inc. (SKYE) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Investors to Seek Compensation for Alleged Wrongdoings
NEW YORK, NY / ACCESSWIRE / August 11, 2024 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Skye Bioscience, Inc. ("Skye" or "the Company") (NASDAQ:SKYE). Investors who purchased Skye securities are encouraged to obtain additional information and assist the investigation by visiting the firm's site: bgandg.com/SKYE.
Skye Being Investigated on Behalf of Skye Bioscience, Inc. Investors. Contact Levi & Korsinsky For Details.
NEW YORK, NY / ACCESSWIRE / August 10, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of Skye Bioscience, Inc. ("Skye") (NASDAQ:SKYE) concerning possible violations of federal securities laws. Skye issued a press release on June 10, 2024, "announc[ing] that its Phase 2a clinical trial of SBI-100 Ophthalmic Emulsion ("OE") in patients with primary open-angle glaucoma "POAG") or ocular hypertension ("OHT") did not meet its primary endpoint for lowering intraocular pressure ("IOP").
Skye Bioscience Inc Investors Encouraged to Participate in Fraud Investigation With The Schall Law Firm
LOS ANGELES, CA / ACCESSWIRE / August 9, 2024 / The Schall Law Firm , a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Skye Bioscience, Inc. ("Skye" or "the Company") (NASDAQ: SKYE ) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.
SKYE ALERT: Levi & Korsinsky Reminds Investors of an Investigation Involving Possible Securities Fraud Violations by Skye Bioscience, Inc.
NEW YORK, NY / ACCESSWIRE / August 9, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of Skye Bioscience, Inc. ("Skye") (NASDAQ:SKYE) concerning possible violations of federal securities laws. Skye issued a press release on June 10, 2024, "announc[ing] that its Phase 2a clinical trial of SBI-100 Ophthalmic Emulsion ("OE") in patients with primary open-angle glaucoma "POAG") or ocular hypertension ("OHT") did not meet its primary endpoint for lowering intraocular pressure ("IOP").
Lost Money on Skye Bioscience, Inc.(SKYE)? You May Have Been Affected by Fraud- Contact Levi & Korsinsky
NEW YORK, NY / ACCESSWIRE / August 8, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of Skye Bioscience, Inc. ("Skye") (NASDAQ:SKYE) concerning possible violations of federal securities laws. Skye issued a press release on June 10, 2024, "announc[ing] that its Phase 2a clinical trial of SBI-100 Ophthalmic Emulsion ("OE") in patients with primary open-angle glaucoma "POAG") or ocular hypertension ("OHT") did not meet its primary endpoint for lowering intraocular pressure ("IOP").
Skye Bioscience Inc Investors Can Join Fraud Investigation With The Schall Law Firm
LOS ANGELES, CA / ACCESSWIRE / August 8, 2024 / The Schall Law Firm , a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Skye Bioscience, Inc. ("Skye" or "the Company") (NASDAQ: SKYE ) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.
Levi & Korsinsky Investigates Possible Securities Fraud Violations by Skye Bioscience, Inc. (SKYE)
NEW YORK, NY / ACCESSWIRE / August 8, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of Skye Bioscience, Inc. ("Skye") (NASDAQ:SKYE) concerning possible violations of federal securities laws. Skye issued a press release on June 10, 2024, "announc[ing] that its Phase 2a clinical trial of SBI-100 Ophthalmic Emulsion ("OE") in patients with primary open-angle glaucoma "POAG") or ocular hypertension ("OHT") did not meet its primary endpoint for lowering intraocular pressure ("IOP").
Skye Bioscience, Inc. (SKYE) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Investors to Seek Compensation for Alleged Wrongdoings
NEW YORK, NY / ACCESSWIRE / August 8, 2024 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Skye Bioscience, Inc. ("Skye" or "the Company") (NASDAQ:SKYE). Investors who purchased Skye securities are encouraged to obtain additional information and assist the investigation by visiting the firm's site: bgandg.com/SKYE.
